China Biologic Products (CBPO) Tops Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Caribou Biosciences to halt CAR-T programs, explore sale
- Emera and Canadian Utilities agree to merge in $72B all-share deal
China Biologic Reports Financial Results for the First Quarter of 2019
May 10, 2019 4:30 PM EDT--1Q19 Total Sales Up 15.4% YoY in USD terms, or 22.3% YoY in RMB terms;Net Income Up 19.3% YoY to $37.7 Million;Non-GAAP Adjusted Net Income Up 14.3% YoY in RMB terms --
BEIJING, May 10, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the first quarter of 2019.
First Quarter 2019 Financial Highlights
Total sales in the first quarter of 2019 increased by 22.3% in RMB terms and... More


